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Skp2 and its cofactor Cks1 are the substrate-targeting subunits of
the SCFSkp2–Cks1 (Skp1/Cul1/F-box protein) ubiquitin ligase
complex that regulates entry into S phase by inducing the
degradation of the cyclin-dependent kinase inhibitors p21 and
p27 (ref. 1). Skp2 is an oncoprotein that often shows increased
expression in human cancers2; however, the mechanism that
regulates its cellular abundance is not well understood. Here
we show that both Skp2 and Cks1 proteins are unstable in G1 and
that their degradation is mediated by the ubiquitin ligase APC/
CCdh1 (anaphase-promoting complex/cyclosome and its activator
Cdh1). Silencing of Cdh1 by RNA interference in G1 cells
stabilizes Skp2 and Cks1, with a consequent increase in p21
and p27 proteolysis. Depletion of Cdh1 also increases the per-
centage of cells in S phase, whereas concomitant downregulation
of Skp2 reverses this effect, showing that Skp2 is an essential
target of APC/CCdh1. Expression of a stable Skp2 mutant that
cannot bind APC/CCdh1 induces premature entry into S phase.
Thus, the induction of Skp2 and Cks1 degradation in G1 rep-
resents a principal mechanism by which APC/CCdh1 prevents the
unscheduled degradation of SCFSkp2–Cks1 substrates and main-
tains the G1 state.
We examined the cell-cycle regulation of Skp2 and Cks1 proteins
and found that they decreased considerably in late M phase and
G1, and were induced again as cells approached S phase (Fig. 1a). To
assess whether the reduction in Skp2 and Cks1 was due to
protein destabilization, we measured their half-lives in prometa-
phase cells and in cells released from a prometaphase block for 1 h.
We found that both Skp2 and Cks1 are more stable in prometaphase
than in late M/early G1 (Fig. 1b). Furthermore, in cells exiting the
cell cycle, Cks1 was found to decrease in parallel with Skp2 (Fig. 1c),
which has been previously reported to decrease in response to
serum deprivation3. Treatment with the proteasome inhibitor ZLLL
prevented the downregulation of both Skp2 and Cks1 (Fig. 1d).
Thus, we conclude that Skp2 and Cks1 proteins are unstable in
G0/G1.
The oscillations of Skp2 and Cks1 roughly paralleled those of
cyclin A and cyclin B (Fig. 1a), which suggested that they might be
degraded through a similar mechanism. We therefore investigated
the involvement of the ubiquitin ligase APC/C4 in controlling the
degradation of Skp2 and Cks1. Because APC/C is regulated by its
association with one of two activator proteins, Cdh1 and Cdc20,
we transfected 293T cells with a construct expressing either Skp2
(Fig. 1e) or Cks1 (Fig. 1f), along with a construct expressing Cdh1
or Cdc20. Enforced expression of Cdh1 resulted in a considerable
                   
               
 
      
      
        
      
Figure 1 In vivo degradation of Skp2 and Cks1 is stimulated by Cdh1. a–h, Immunoblots.
a, HeLa cells were released from nocodazole-induced prometaphase arrest and collected
at the indicated times. b, Prometaphase cells were replated for 1 h in the presence
(prometaphase) or absence (late M/early G1) of nocodazole. Cycloheximide (CHX) was
then added and cell extracts were prepared at the indicated times. The results are
quantified in the graphs on the right. c, Rat-1 cells infected with a retrovirus expressing
Flag-tagged Cks1 were serum-deprived and extracts were prepared at the indicated
times. d, Rat-1 cells were serum-deprived for 24 h and the proteasome inhibitor ZLLL (þ)
or vehicle alone (2) was added for the last 6 h. e, Coexpression of Flag–Skp2 and
either HA–Cdh1 or HA–Cdc20 in 293T cells. f, Coexpression of Flag–Cks1 and either
HA–Cdh1 or HA–Cdc20 in 293T cells. g, HeLa cells were transfected with Flag–Skp2
with or without HA–Cdh1. Twenty-four hours after transfection, cells were treated
with CHX. Skp2 expression is quantified in the graph below. h, HeLa cells were
transfected with Flag–Cks1 with or without HA–Cdh1. The half-life of Cks1 was analysed
as in g.
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decrease in the steady-state amounts of both proteins, whereas
overexpression of Cdc20 had no effect. Notably, the decrease in
Skp2 and Cks1 expression correlated with their destabilization
(Fig. 1g, h).
We next used small interfering RNAs (siRNAs) to reduce the
expression of Cdh1. After transfection with siRNA, prometaphase
HeLa cells were collected and replated in fresh medium. Cells
transfected with siRNA targeting Cdh1 showed no G1-specific
reduction in Skp2 and Cks1, a much less pronounced upregulation
of p21 and p27 as compared with control cells (Fig. 2a), and an
increase in the half-life of both Skp2 and Cks1 (Fig. 2b).
We also silenced Cdh1 expression in T98G cells exiting the cell
cycle (as shown by the accumulation of p27; Fig. 2c). Silencing of
Cdh1 prevented the degradation of Skp2 and Cks1 for up to 36 h
after serum removal, when the effect of the siRNA started to wane,
as judged by the recovery of Cdh1. It has been suggested that
Skp2 downregulation in G0/G1 is due to Cul1-dependent auto-
ubiquitination3; however, depletion of Cul1 did not prevent the
degradation of Skp2 and Cks1 (Fig. 2c).
Downregulation of Cdh1 resulted in an increase in the number of
HeLa cells incorporating 5-bromodeoxyuridine (BrdU; Fig. 2d).
Notably, co-depletion of Skp2 reversed the stimulatory effect
induced by Cdh1 inhibition. Furthermore, single-cell immuno-
fluorescence analysis (Fig. 2d, bottom) showed that Cdh1-depleted
cells progressed faster through S phase, as 78.2 ^ 1.4% of these cells
showed a diffuse BrdU staining typical of advanced S phase, rather
than the distinct foci of BrdU incorporation characteristic of initial
DNA replication. By contrast, diffuse BrdU staining was present in
only 65.7 ^ 2.1% of control cells, 37.8 ^ 0.5% of Skp2-depleted
cells and 35 ^ 2.1% of cells depleted in both Cdh1 and Skp2. Taken
together, these results show that in G0/G1 the stability of Skp2 and
Cks1 is regulated by APC/CCdh1 and that Skp2 is an essential target
of Cdh1, because in Skp2-depleted cells Cdh1 downregulation is
insufficient to promote DNA replication.
Additional key observations could be derived from the siRNA
experiments with regard to the cell cycle in the presence of reduced
amounts of Cdh1. First, cells still exited mitosis with normal
kinetics, as judged by the degradation of cyclin A and cyclin B
and the disappearance of phosphorylation on Ser 10 of histone H3
(Fig. 2a). By contrast, silencing of Cdc20 delayed mitotic exit by
about 1 h (data not shown). Second, cyclin A and cyclin B are
normally downregulated in mitosis, but cyclin A re-accumulated
at G1/S slightly earlier in Cdh1-silenced cells than in control cells
(Fig. 2a, time points 4 and 6). This effect was even more evident in
                   
                    
          
 
 
  
 
 
Figure 2 Cdh1 silencing stabilizes Skp2 and Cks1 in G1 and G0. a–c, Immunoblots.
a, HeLa cells were transfected with siRNA corresponding to a non-relevant mRNA (control
siRNA) or to Cdh1 mRNA. Twelve hours after the last transfection, nocodazole was added
for 16 h. Prometaphase cells were collected and replated in fresh medium for the
indicated times. b, Silencing of Cdh1 and synchronization were done as in a.
Prometaphase cells were replated in drug-free medium for 1 h before CHX was added for
the indicated times. The results are quantified in the graphs on the right. c, Silencing of
Cdh1 and Cul1 was done as in a, except that T98G cells were used. Twenty-four hours
after the last transfection, cells were deprived of serum for the indicated times. d, Top,
HeLa cells were transfected with the indicated siRNAs and labelled with BrdU for 60 min,
and the percentage of BrdU-positive cells was determined by immunofluorescence;
bottom, representative cells visualized by immunofluorescence using an antibody against
BrdU. e, Cells treated as in d were analysed by immunoblotting.
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asynchronous cells, in which the silencing of Cdh1 induced a
marked increase in cyclin A (Fig. 2e). Third, the accumulation of
p27 and p21 was markedly reduced in cells re-entering G1 from
mitosis (Fig. 2a) and in asynchronous cells (Fig. 2e), but not in
serum-starved cells (Fig. 2c and data not shown). Thus, Cdh1
seems to be rate limiting for the accumulation of SCFSkp2–Cks1
substrates in cycling cells, but not in cells withdrawing from the
cell cycle.
Substrates of APC/C are often characterized by the presence of a
‘destruction box’ (D-box), which was first identified in cyclin B as a
stretch of nine amino acids (RxxLxxIxN) that when mutated
stabilizes the protein4. However, many substrates contain only the
minimal RxxL motif in their D-boxes, which together with
additional regions in the substrate regulate their degradation by
APC/C. We identified five RxxL motifs in human Skp2 that
potentially might be D-boxes (amino acids 3–6, 84–87, 234–237,
294–297 and 415–418), but no other known putative Cdh1 recog-
nition motifs (such as the KEN-box or A-box). One potential D-box
(amino acids 234–237) is located in a leucine-rich repeat, which is
part of the putative substrate-binding motif and therefore less likely
to be also a recognition site for Cdh1.
We mutated the arginine and leucine residues in the other four
motifs to alanine and determined the stabilities of these D-box
mutants and three Skp2 deletion mutants in 293T cells over-
expressing Cdh1. Of these Skp2 mutants, one with a mutation at
the very amino terminus (D-box I) and two N-terminal deletion
mutants, Skp2(D45) and Skp2(D94), were resistant to the effect of
overexpressed Cdh1 (Fig. 3a). Notably, a Skp2 mutant lacking the
F-box, Skp2(DF), was efficiently downregulated by Cdh1, showing
that Skp2 does not need to be part of an SCF complex to be a
substrate of APC/C. We also investigated the stabilities of the D-
box I and deletion mutants in Rat-1 fibroblasts exiting the cell
cycle. Skp2 was monitored by immunoblotting with an antibody
against human Skp2 that does not recognize endogenous rat Skp2
(ref. 5). All three Skp2 mutants were clearly stabilized under
conditions that promoted rapid degradation of wild-type Skp2
(Fig. 3b), confirming that the degradation of Skp2 is dependent
on D-box I.
We next investigated the requirements for Cdh1-mediated degra-
dation of Cks1. There is one RxxL motif at the carboxy terminus of
Cks1 (amino acids 70–73), which when mutated prevented Cdh1-
induced degradation (Fig. 3c), suggesting that this region represents
a bona fide D-box. In addition, a Cks1 mutant that cannot bind
cyclin-dependent kinases (CDKs), Glu63Gln, and two mutants that
cannot bind Skp2, Ser41Glu and Asn45Arg (ref. 6), were still
downregulated when Cdh1 was coexpressed (Fig. 3c), showing
that stable binding to either CDKs or Skp2 is not a prerequisite
for APC/CCdh1-mediated degradation of Cks1.
Furthermore, we found that Skp2 physically interacts with Cdh1
but not with Cdc20 (Fig. 3d), confirming the specificity of Cdh1 for
this substrate. Similarly, Cks1 co-immunoprecipitated with Cdh1
and to a lesser extent with Cdc20 (Fig. 3e), which is not surprising
because Cks1 binds to APC/CCdc20 to promote its phosphorylation7.
Notably, wild-type Skp2, but not Skp2(D94), was detected in anti-
Cdh1 immunoprecipitates (Fig. 3f). Although the Skp2 D-box I
mutant and Skp2(D45) were more stable than the wild-type protein
(Fig. 3a, b), they still bound Cdh1 (Fig. 3f). These results show that a
region of Skp2 between amino acids 46 and 94 mediates the binding
between Skp2 and Cdh1, in line with the notion that the RxxL motif
is an APC/C recognition motif but does not necessarily mediate
a stable interaction with this ligase. The importance of the Skp2
N-terminal region was further shown by the ability of APC/CCdh1 to
ubiquitinate in vitro wild-type Skp2 but not Skp2(D94) (Fig. 3g). In
contrast to Skp2, we were unable to in vitro ubiquitinate Cks1 using
APC/CCdh1, suggesting that an essential factor was missing or that
Cks1, although downstream of APC/CCdh1, might not be its direct
substrate.
To examine further the biological significance of Skp2 destruc-
 
 
 
  
 
 
 
                         
             
 
   
 
   
 
 
   
 
        
 
           
Figure 3 Requirements for APC/CCdh1-mediated degradation of Skp2 and Cks1.
a–f, Immunoblots. a, Expression of Flag-tagged wild-type Skp2 or the indicated Skp2
mutants with or without HA–Cdh1 in 293T cells. b, Rat-1 cells were infected with
retroviruses expressing human wild-type Skp2 or the indicated Skp2 mutants, and
deprived of serum for the indicated times. c, Expression of Flag-tagged wild-type Cks1 or
the indicated Cks1 mutants with or without HA–Cdh1 in 293T cells. d, Skp2 and either
HA–Cdh1 or HA–Cdc20 were expressed in 293T cells, and ZLLL was added 6 h before the
cells were collected. Cell extracts were immunoprecipitated (IP) with an antibody against
HA and analysed by immunoblotting (IB). e, As d, except that Cks1 rather than Skp2 was
expressed. f, As d, but with the indicated Skp2 mutants. g, Immunopurified APC/C
supplemented with recombinant Cdh1 ubiquitinates in vitro translated wild-type Skp2 but
not Skp2(D94). The brackets mark a ladder of bands of relative molecular mass.45,000
corresponding to polyubiquitinated Skp2.
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tion, we evaluated the effect of expressing the stable Skp2(D94)
mutant in synchronized cells. As compared with control cells, cells
expressing Skp2(D94) showed accelerated degradation of p21 and
p27, and stabilization of endogenous Skp2 and Cks1 in G1 (Fig. 4a).
Notably, these cells progressed considerably faster into S phase
(Fig. 4b), although not to the same extent as Cdh1-depleted cells
(Fig. 4c). This difference is probably due to the fact that Skp2 is
an essential, but not the only, substrate that is degraded through
APC/CCdh1 to prevent premature entry into S phase. Extensive
overexpression of Skp2 achieved with adenoviral vectors accelerates
S-phase entry8, whereas physiological amounts of Skp2 expressed
from retroviral vectors are subject to regulated proteolysis and
are unable to force cells into S phase (refs 3, 5, and Fig. 3b). By
contrast, the expression of physiological amounts of a stable Skp2
mutant in G1 induced premature S-phase entry. These results show
that Skp2 destruction is an essential event for proper cell-cycle
control.
Experiments in cultured cells and transgenic mice have shown
that Skp2 is the product of a proto-oncogene2. In human car-
cinomas and lymphomas, p27 destabilization is predictive of
poor prognosis and correlates with high concentrations of Skp2
(ref. 9). We have shown here that the degradation of Skp2 and
Cks1 is controlled by APC/CCdh1, which represents a principal
mechanism to maintain the G1 state and to avoid premature
entry into S phase, a potential cause of genetic instability. Dereg-
ulation of this mechanism might contribute to overexpression of
Skp2 and Cks1 and thereby promote uncontrolled proliferation in
cancer cells. A
Methods
Cell culture and biochemistry
Cell culture and synchronization of HeLa, Rat-1, 293T and T98G cells were done as
described3,5,10. Antibodies against Skp2, Skp1, p27, p21, cyclin A, cyclin B, Cul1, phospho-
histone H3, BrdU, haemagglutinin (HA) and Flag have been described5,10. Antibodies
against Cdh1 and Cdc20 were a gift from J. Lukas. An antibody against human Cks1
(which does not crossreact with Cks2) was generated in collaboration with Zymed.
Immunoblot analysis, immunoprecipitations and immunofluorescence were done as
described10. We carried out in vitro ubiquitination as described11, except that we used
extracts from serum-deprived T98G cells.
Plasmids, transfections, infections and siRNAs
Skp2 and Cks1 mutants were generated using the QuickChange Site-directed
Mutagenesis kit (Stratagene). Cell transfections and retroviral infections were done as
described10,12. The siRNA oligonucleotide sequences were 5 0 -AATGAGAAGTCT
CCCAGTCAGdTdT-3
0
(Cdh1), 5
0
-AAGGGAGUGACAAAGACUUUGdTdT-3
0
or
5
0
-AAUCUAAGCCUGGAA GGCCUGdTdT-3
0
(Skp2) and 5
0
-UAGACAUUGGGUU
CGCCGUdTdT-3 0 (Cul1).
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Figure 4 Biological relevance of Skp2 degradation. a, HeLa cells were either mock
infected or infected with a retrovirus expressing Skp2(D94). After nocodazole
treatment, prometaphase cells were replated in fresh medium for the indicated times.
Cells were collected and analysed by immunoblotting. b, The percentage of BrdU-
positive cells was determined in three independent experiments done as in a. c, The
percentage of BrdU-positive cells was determined in three independent experiments
done as in Fig. 2d, with the exception that cells were synchronized as in Fig. 2a and
released from prometaphase for the indicated times before BrdU was added for
30 min.
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